Vaxcyte Q1 net loss widens to $320.6 million; R&D expenses jump to $312.8 million

Vaxcyte

Vaxcyte

PCVX

0.00
  • Vaxcyte posted a net loss of USD 320.6 million for first-quarter 2026, widening from USD 140.7 million a year earlier, while R&D expense more than doubled to USD 312.8 million.
  • Cash, cash equivalents and investments rose to USD 2.74 billion as of March 31, 2026 from USD 2.44 billion at year-end 2025, including USD 601.8 million in net proceeds from a February equity offering.
  • Enrollment is now complete across OPUS-1, OPUS-2 and OPUS-3 Phase 3 adult trials of VAX-31, with 6,191 adults dosed; OPUS-1 topline safety, tolerability and immunogenicity data are expected in fourth-quarter 2026.
  • OPUS-2 and OPUS-3 results are expected in first-half 2027, while topline Phase 2 infant dose-finding data for VAX-31 are expected by end of first-half 2027.
  • Management said it remains on track for planned BLA submission and potential U.S. commercial launch, with a Phase 1 adult study for Group A Strep candidate VAX-A1 slated to start in mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605061605PRIMZONEFULLFEED9714648) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.